Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Walmart Stores Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Walmart Stores Inc trades at $114.52 (market cap $906.43B). The key difference: Walmart Stores Inc is far larger — about 22.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Walmart Stores Inc pays a 0.87% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMT | |
|---|---|---|
Market Cap | $39.89B | $906.43B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $134.20 |
52-Week Low | $278.09 | $94.40 |
Enterprise Value | $38.15B | $969.88B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Walmart (WMT) trades at $113.9, up 1.51% today, amid mixed signals. The stock shows bearish technical indicators but strong fundamentals with consistent earnings beats and revenue growth to $681.0 billion in 2025. Recent news highlights Walmart's AI initiatives and philanthropic efforts, while competition intensifies as Amazon surpasses it in Fortune 500 revenue ranking.
The outlook remains positive with a consensus price target of $141.64, implying significant upside. Risks include competitive pressures and economic sensitivity, but Walmart's scale, dividend stability, and operational efficiency support a bullish long-term view for investors seeking defensive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
